Arcturus Therapeutics Holdings Inc. (ARCT): Results of Operations and Financial Condition
Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol
How this was made
The 30-second read
Why it matters
Key trading inputs are (1) time-stamped pipeline milestones for ARCT-032 and ARCT-810, and (2) the CSL Seqirus termination and settlement that returns global rights to KOSTAIVE and provides $12M cash plus ~$16M released liabilities/R&D credits, improving financial flexibility.
Market read
Investors get a clearer near-to-mid-term roadmap (Q3 2026 ARCT-810 data/regulatory plan; Q4 2026 ARCT-032 Phase 3 decision) and improved balance-sheet support from the CSL Seqirus settlement, but the release lacks new efficacy readouts.
What to watch
Thermo Fisher’s role is manufacturing and services, but the article does not quantify cost, timeline, or regulatory risk; also, revenue declines are tied to the collaboration wind-down, which may pressure near-term financial optics.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and pipeline/corporate updates for Arcturus Therapeutics.
Ticker impact
Arcturus reported Q2 2026 results and said ARCT-032 Phase 2 enrollment is on schedule, with Phase 3 decision expected in Q4 2026.
Moderately positive bias into the next quarter as investors price in Phase 3 go/no-go timing and improved funding visibility.
The filing adds concrete, time-bound program milestones (Phase 3 expected Q4 2026, ARCT-810 data/regulatory plan expected Q3 2026) and a $12M cash inflow plus ~$16M released liabilities/credits from the CSL Seqirus settlement, which can reduce financing overhang.
Market effects
Reinforces investor focus on mRNA rare-disease programs with clear Phase 2-to-Phase 3 transition timelines and manufacturing/partner support.
Limited direct regional read-through; clinical enrollment spans U.S., Israel, and Turkey but the disclosure is company-specific.
Global rights return for KOSTAIVE and infectious disease vaccines may affect competitive positioning in multiple geographies, though details are constrained by existing Japan season arrangements.
Counterpoint
The filing highlights progress but does not provide new clinical efficacy results; the Phase 3 decision is still conditional on Phase 2 outcomes.
Key entities
- issuerArcturus Therapeutics Holdings Inc.
Nasdaq-listed mRNA medicines company; disclosed Q2 2026 financials, ARCT-032 and ARCT-810 progress, and the CSL Seqirus settlement.
- collaboration_partnerThermo Fisher Scientific
Collaborator for ARCT-032 Phase 3 manufacturing and clinical research services under a stated agreement.
- collaboration_partnerCSL Seqirus
Terminated sa-mRNA collaboration; to pay $12M cash and release ~$16M in liabilities/credits to Arcturus.
- partnerMeiji Seika Pharma
Has existing arrangements for the 2026-2027 Japan season referenced in the KOSTAIVE rights return.
